Current and emerging treatment options for endometriosis

被引:120
|
作者
Ferrero, Simone [1 ,2 ]
Evangelisti, Giulio [1 ,2 ]
Barra, Fabio [1 ,2 ]
机构
[1] Osped Policlin San Martino, Acad Unit Obstet & Gynecol, Largo R Benzi 10, I-16132 Genoa, Italy
[2] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
关键词
Endometriosis; combined oral contraceptives; progestins; gonadotropin-releasing hormone agonist; aromatase inhibitors; gonadotropin-releasing hormone antagonist; anti-angiogenetic; anti-oxidant; immunomodulators; DEPOT MEDROXYPROGESTERONE ACETATE; CHRONIC PELVIC PAIN; NECROSIS-FACTOR-ALPHA; ESTROGEN-RECEPTOR MODULATOR; ONLY CONTRACEPTIVE PILL; ORAL GNRH ANTAGONIST; LEUPROLIDE ACETATE; DOUBLE-BLIND; RECTOVAGINAL ENDOMETRIOSIS; NORETHISTERONE ACETATE;
D O I
10.1080/14656566.2018.1494154
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Pharmacotherapy has a pivotal role in the management of endometriosis with long-term treatments balancing clinical efficacy (control of pain symptoms and prevention of recurrence of the disease after surgery) with an acceptable safety profile. Treatment choice is based on several factors including age and patient preference, reproductive plans, intensity of pain, severity of disease and incidence of adverse effects. Areas covered: The aim of this review is to provide the reader with a complete overview of drugs that are currently available or are under investigation for the treatment of endometriosis highlighting on-going clinical trials. Expert opinion: Almost all of the available treatment options for endometriosis suppress ovarian function and are not curative. Combined oral contraceptives and progestins are commonly administered to these patients in order to ameliorate pain symptoms. Gonadotropin-releasing hormone-agonists are prescribed when first-line therapies are ineffective, not tolerated or contraindicated. Aromatase inhibitors should be reserved only for women who are refractory to other treatments. Amongst the drugs under development, gonadotropin-releasing hormone antagonists have shown the most promising results. Presently, are a number of potential therapies currently in pre-clinical or early clinical studies which may alter treatment strategies in the future although further studies are necessary.
引用
收藏
页码:1109 / 1125
页数:17
相关论文
共 50 条
  • [1] Current and Emerging Options in the Treatment of Onychomycosis
    Elewski, Boni
    Pariser, David
    Rich, Phoebe
    Scher, Richard K.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2013, 32 (02) : S9 - S12
  • [2] Gastroparesis: a review of current and emerging treatment options
    Enweluzo, Chijioke
    Aziz, Fahad
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2013, 6 : 161 - 165
  • [3] Birdshot uveitis: current and emerging treatment options
    Menezo, Victor
    Taylor, Simon R. J.
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 73 - 81
  • [4] Current and emerging treatment options in the management of lupus
    Jordan, Natasha
    D'Cruz, David
    IMMUNOTARGETS AND THERAPY, 2016, 5 : 9 - 20
  • [5] Chronic Pruritus: Current and Emerging Treatment Options
    Pereira, Manuel P.
    Staender, Sonja
    DRUGS, 2017, 77 (09) : 999 - 1007
  • [6] Posttraumatic epilepsy: current and emerging treatment options
    Paiva, Wellingson Silva
    Mello, Luiz Eugenio
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 2159 - 2160
  • [7] Current and emerging treatment options for Angelman syndrome
    Keary, Christopher J.
    McDougle, Christopher J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, : 835 - 844
  • [8] Review of current and emerging treatment options in acromegaly
    Muhammad, A.
    van der Lely, A. J.
    Neggers, S. J. C. M. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2015, 73 (08): : 362 - 367
  • [9] Current and emerging treatment options for Graves' hyperthyroidism
    Abraham, Prakash
    Acharya, Shamasunder
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 29 - 40
  • [10] Current Treatment Options and Emerging Agents for Schizophrenia
    Correll, Christoph U.
    JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (03)